Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $25.50.

KURA has been the subject of several recent research reports. UBS Group reduced their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Friday, April 4th. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 8th.

Kura Oncology Stock Performance

Shares of KURA stock opened at $6.03 on Wednesday. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $23.48. The company’s fifty day simple moving average is $7.24 and its 200-day simple moving average is $10.67. The firm has a market cap of $486.95 million, a PE ratio of -2.56 and a beta of 0.83. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Equities research analysts expect that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last quarter. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtus ETF Advisers LLC increased its holdings in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares during the period. Harbor Advisors LLC acquired a new stake in Kura Oncology during the fourth quarter worth approximately $87,000. Pallas Capital Advisors LLC bought a new position in Kura Oncology during the 1st quarter worth $66,000. E Fund Management Co. Ltd. acquired a new position in Kura Oncology in the 4th quarter valued at $90,000. Finally, Corton Capital Inc. bought a new stake in shares of Kura Oncology during the 4th quarter valued at $99,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.